Sort by
Items per page

Send to

Choose Destination

Search results

Items: 20


Lysosomes support the degradation, signaling, and mitochondrial metabolism necessary for human epidermal differentiation.

Monteleon CL, Agnihotri T, Dahal A, Liu M, Rebecca VW, Beatty GL, Amavaradi RK, Ridky TW.

J Invest Dermatol. 2018 Mar 8. pii: S0022-202X(18)30216-1. doi: 10.1016/j.jid.2018.02.035. [Epub ahead of print]


Dimeric quinacrines as chemical tools to identify PPT1, a new regulator of autophagy in cancer cells.

Nicastri MC, Rebecca VW, Amaravadi RK, Winkler JD.

Mol Cell Oncol. 2017 Nov 30;5(1):e1395504. doi: 10.1080/23723556.2017.1395504. eCollection 2018.


Resistance mechanisms to genetic suppression of mutant NRAS in melanoma.

Robinson JP, Rebecca VW, Kircher DA, Silvis MR, Smalley I, Gibney GT, Lastwika KJ, Chen G, Davies MA, Grossman D, Smalley KSM, Holmen SL, VanBrocklin MW.

Melanoma Res. 2017 Dec;27(6):545-557. doi: 10.1097/CMR.0000000000000403.


ALDH1A1 and HLTF modulate the activity of lysosomal autophagy inhibitors in cancer cells.

Piao S, Ojha R, Rebecca VW, Samanta A, Ma XH, Mcafee Q, Nicastri MC, Buckley M, Brown E, Winkler JD, Gimotty PA, Amaravadi RK.

Autophagy. 2017;13(12):2056-2071. doi: 10.1080/15548627.2017.1377377. Epub 2017 Oct 5.


A Unified Approach to Targeting the Lysosome's Degradative and Growth Signaling Roles.

Rebecca VW, Nicastri MC, McLaughlin N, Fennelly C, McAfee Q, Ronghe A, Nofal M, Lim CY, Witze E, Chude CI, Zhang G, Alicea GM, Piao S, Murugan S, Ojha R, Levi SM, Wei Z, Barber-Rotenberg JS, Murphy ME, Mills GB, Lu Y, Rabinowitz J, Marmorstein R, Liu Q, Liu S, Xu X, Herlyn M, Zoncu R, Brady DC, Speicher DW, Winkler JD, Amaravadi RK.

Cancer Discov. 2017 Nov;7(11):1266-1283. doi: 10.1158/2159-8290.CD-17-0741. Epub 2017 Sep 12.


ATG5 Mediates a Positive Feedback Loop between Wnt Signaling and Autophagy in Melanoma.

Ndoye A, Budina-Kolomets A, Kugel CH 3rd, Webster MR, Kaur A, Behera R, Rebecca VW, Li L, Brafford PA, Liu Q, Gopal YNV, Davies MA, Mills GB, Xu X, Wu H, Herlyn M, Nicastri MC, Winkler JD, Soengas MS, Amaravadi RK, Murphy ME, Weeraratna AT.

Cancer Res. 2017 Nov 1;77(21):5873-5885. doi: 10.1158/0008-5472.CAN-17-0907. Epub 2017 Sep 8.


Inhibition of proliferation and invasion in 2D and 3D models by 2-methoxyestradiol in human melanoma cells.

Massaro RR, Faião-Flores F, Rebecca VW, Sandri S, Alves-Fernandes DK, Pennacchi PC, Smalley KSM, Maria-Engler SS.

Pharmacol Res. 2017 May;119:242-250. doi: 10.1016/j.phrs.2017.02.013. Epub 2017 Feb 14.


Phase i trials in melanoma: A framework to translate preclinical findings to the clinic.

Kim E, Rebecca VW, Smalley KS, Anderson AR.

Eur J Cancer. 2016 Nov;67:213-222. doi: 10.1016/j.ejca.2016.07.024. Epub 2016 Sep 28.


Emerging strategies to effectively target autophagy in cancer.

Rebecca VW, Amaravadi RK.

Oncogene. 2016 Jan 7;35(1):1-11. doi: 10.1038/onc.2015.99. Epub 2015 Apr 20. Review.


Vertical inhibition of the MAPK pathway enhances therapeutic responses in NRAS-mutant melanoma.

Rebecca VW, Alicea GM, Paraiso KH, Lawrence H, Gibney GT, Smalley KS.

Pigment Cell Melanoma Res. 2014 Nov;27(6):1154-8. doi: 10.1111/pcmr.12303. Epub 2014 Sep 1.


Change or die: targeting adaptive signaling to kinase inhibition in cancer cells.

Rebecca VW, Smalley KS.

Biochem Pharmacol. 2014 Oct 15;91(4):417-25. doi: 10.1016/j.bcp.2014.07.031. Epub 2014 Aug 12. Review.


Evaluating melanoma drug response and therapeutic escape with quantitative proteomics.

Rebecca VW, Wood E, Fedorenko IV, Paraiso KH, Haarberg HE, Chen Y, Xiang Y, Sarnaik A, Gibney GT, Sondak VK, Koomen JM, Smalley KS.

Mol Cell Proteomics. 2014 Jul;13(7):1844-54. doi: 10.1074/mcp.M113.037424. Epub 2014 Apr 23.


Inhibition of autophagy enhances the effects of the AKT inhibitor MK-2206 when combined with paclitaxel and carboplatin in BRAF wild-type melanoma.

Rebecca VW, Massaro RR, Fedorenko IV, Sondak VK, Anderson AR, Kim E, Amaravadi RK, Maria-Engler SS, Messina JL, Gibney GT, Kudchadkar RR, Smalley KS.

Pigment Cell Melanoma Res. 2014 May;27(3):465-78. doi: 10.1111/pcmr.12227. Epub 2014 Feb 21.


Inhibition of Wee1, AKT, and CDK4 underlies the efficacy of the HSP90 inhibitor XL888 in an in vivo model of NRAS-mutant melanoma.

Haarberg HE, Paraiso KH, Wood E, Rebecca VW, Sondak VK, Koomen JM, Smalley KS.

Mol Cancer Ther. 2013 Jun;12(6):901-12. doi: 10.1158/1535-7163.MCT-12-1003. Epub 2013 Mar 28.


GSK3β inhibition blocks melanoma cell/host interactions by downregulating N-cadherin expression and decreasing FAK phosphorylation.

John JK, Paraiso KH, Rebecca VW, Cantini LP, Abel EV, Pagano N, Meggers E, Mathew R, Krepler C, Izumi V, Fang B, Koomen JM, Messina JL, Herlyn M, Smalley KS.

J Invest Dermatol. 2012 Dec;132(12):2818-27. doi: 10.1038/jid.2012.237. Epub 2012 Jul 19.


A brief history of melanoma: from mummies to mutations.

Rebecca VW, Sondak VK, Smalley KS.

Melanoma Res. 2012 Apr;22(2):114-22. doi: 10.1097/CMR.0b013e328351fa4d. Review.


The HSP90 inhibitor XL888 overcomes BRAF inhibitor resistance mediated through diverse mechanisms.

Paraiso KH, Haarberg HE, Wood E, Rebecca VW, Chen YA, Xiang Y, Ribas A, Lo RS, Weber JS, Sondak VK, John JK, Sarnaik AA, Koomen JM, Smalley KS.

Clin Cancer Res. 2012 May 1;18(9):2502-14. doi: 10.1158/1078-0432.CCR-11-2612. Epub 2012 Feb 20.


Fibroblasts contribute to melanoma tumor growth and drug resistance.

Flach EH, Rebecca VW, Herlyn M, Smalley KS, Anderson AR.

Mol Pharm. 2011 Dec 5;8(6):2039-49. doi: 10.1021/mp200421k. Epub 2011 Nov 8.


PTEN loss confers BRAF inhibitor resistance to melanoma cells through the suppression of BIM expression.

Paraiso KH, Xiang Y, Rebecca VW, Abel EV, Chen YA, Munko AC, Wood E, Fedorenko IV, Sondak VK, Anderson AR, Ribas A, Palma MD, Nathanson KL, Koomen JM, Messina JL, Smalley KS.

Cancer Res. 2011 Apr 1;71(7):2750-60. doi: 10.1158/0008-5472.CAN-10-2954. Epub 2011 Feb 11.


Tumor heterogeneity and strategies to overcome kinase inhibitor resistance in cancer: lessons from melanoma.

Rebecca VW, Smalley KS.

Expert Opin Investig Drugs. 2011 Feb;20(2):137-40. doi: 10.1517/13543784.2011.546218. No abstract available.

Supplemental Content

Loading ...
Support Center